VINORELBINE TARTRATE FOR INJECTION SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

VINORELBINE (VINORELBINE TARTRATE)

から入手可能:

TEVA CANADA LIMITED

ATCコード:

L01CA04

INN（国際名）:

VINORELBINE

投薬量:

10MG

医薬品形態:

SOLUTION

構図:

VINORELBINE (VINORELBINE TARTRATE) 10MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

1/5ML

処方タイプ:

Prescription

治療領域:

ANTINEOPLASTIC AGENTS

製品概要:

Active ingredient group (AIG) number: 0126071001; AHFS:

認証ステータス:

APPROVED

承認日:

2014-04-01

製品の特徴

PRODUCT MONOGRAPH
Pr
VINORELBINE TARTRATE FOR INJECTION
Vinorelbine tartrate for injection
10 mg vinorelbine per mL
Antineoplastic Agent
Teva Canada Limited
Date of Preparation:
30 Novopharm Court
March 20, 2014
Toronto, Canada
M1B 2K9
Control No. 172255
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
..............................................................................................................
4
WARNINGS AND PRECAUTIONS
.............................................................................................
4
ADVERSE REACTIONS
...............................................................................................................
7
DRUG INTERACTIONS
.............................................................................................................
12
DOSAGE AND ADMINISTRATION
.........................................................................................
12
OVERDOSAGE
...........................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
15
STORAGE AND STABILITY
.....................................................................................................
16
SPECIAL HANDLING INSTRUCTIONS
..................................................................................
16
PART II: SCIENTIFIC INFORMATION
...................................................................................
18
PHARMACEUTICAL INFORMATION
.....................................................................................
18
CLINICAL TRIALS
...............................................